ObesityPhase 2NCT06683508
A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
A Phase 2 study testing LY3549492 in people with Obesity and Overweight, run by Eli Lilly and Company at 49 sites in United States.
Trial summary
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with obesity or overweight. Participation in the study will last about one year. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Obesity, Overweight
- What is being tested?
- LY3549492
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 288 participants
- Where
- 49 sitesUnited States
- Study dates
- 13 Nov 2024to 4 May 2026
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- W8M-MC-GN01:
- Assigned male at birth
- Assigned female at birth, who are of non-childbearing potential
- W8M-MC-CWMM:
- Have a BMI of
- ≥ 30 kilograms per square meter (kg/m²) or
- ≥ 27 kg/m² and < 30 kg/m² with at least one weight-related comorbidity
- Have had a stable body weight for the 3 months prior to randomization (<5% body weight gain and/or loss)
Who cannot join
- W8M-MC-GN01:
- Have Type 2 Diabetes Mellitus or Type 1 Diabetes Mellitus
- Have a history of acute or chronic pancreatitis
- Have renal impairment
- Individuals who are of childbearing potential
- W8M-MC-CWMM:
Show all 17Show fewer
- Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening.
- Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma.
- Have poorly controlled hypertension.
- Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease.
- Have any of the following cardiovascular conditions within 3 months prior to screening:
- acute myocardial infarction
- cerebrovascular accident (stroke)
- unstable angina, or
- hospitalization due to congestive heart failure.
- Have a history of symptomatic gallbladder disease within the past 2 years
- Have a lifetime history of suicide attempts.
Trial locations and contacts
49 sites in 1 country.
49 sites in 1 country
United States49 sites
Dent Neurologic Institute
Amherst, New York, 14226
Medical Research Partners
Ammon, Idaho, 83406
IMA Clinical Research Austin
Austin, Texas, 78745
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
Chandler, Arizona, 85225
Great Lakes Clinical Trials - Andersonville
Chicago, Illinois, 60640
Great Lakes Clinical Trials - Ravenswood
Chicago, Illinois, 60640
CTI Clinical Research Center
Cincinnati, Ohio, 45212
StudyMetrix Research
City of Saint Peters, Missouri, 63303
Velocity Clinical Research, Dallas
Dallas, Texas, 75230
FutureSearch Trials of Dallas
Dallas, Texas, 75251
Spectrum Medical, Inc.
Danville, Virginia, 24541
Velocity Clinical Research, Syracuse
East Syracuse, New York, 13057
Northeast Research Institute (NERI)
Fleming Island, Florida, 32003
NorCal Medical Research, Inc
Greenbrae, California, 94904
Medication Management
Greensboro, North Carolina, 27405
Tribe Clinical Research, LLC
Greenville, South Carolina, 29607
Indago Research & Health Center, Inc
Hialeah, Florida, 33012
PlanIt Research, PLLC
Houston, Texas, 77079
Velocity Clinical Research, Huntington Park
Huntington Park, California, 90255
Las Vegas Medical Research
Las Vegas, Nevada, 89128
L-MARC Research Center
Louisville, Kentucky, 40213
New Horizon Research Center
Miami, Florida, 33165
Monroe Biomedical Research
Monroe, North Carolina, 28112
Lucas Research, Inc
Morehead City, North Carolina, 28557
Quality Medical Research
Nashville, Tennessee, 37211
Knownwell
Needham, Massachusetts, 02492
Lucida Clinical Trials
New Bedford, Massachusetts, 02740
Lucas Research, Inc.
New Bern, North Carolina, 28562
Suncoast Clinical Research, Inc.
New Port Richey, Florida, 34652
Charter Research - Winter Park
Orlando, Florida, 32803
HOPE Research Institute
Phoenix, Arizona, 85032
North Suffolk Neurology
Port Jefferson Station, New York, 11776
Rochester Clinical Research, LLC
Rochester, New York, 14609
Peninsula Research Associates
Rolling Hills Estates, California, 90274
Tekton Research - Fredericksburg Road
San Antonio, Texas, 78229
Endeavor Clinical Trials
San Antonio, Texas, 78240
Headlands Research - Scottsdale
Scottsdale, Arizona, 85260
NorthShore University Health System
Skokie, Illinois, 60077
Headlands Research - Detroit
Southfield, Michigan, 48034
Clinvest Headlands Llc
Springfield, Missouri, 65807
Stamford Therapeutics Consortium
Stamford, Connecticut, 06905
Charter Research - Lady Lake
The Villages, Florida, 32162
Cotton O'Neil Diabetes & Endocrinology
Topeka, Kansas, 66606
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan, 48098
The Institute for Liver Health II dba Arizona Liver Health-Tucson
Tucson, Arizona, 85712
Diablo Clinical Research, Inc.
Walnut Creek, California, 94598
Central Washington Health Services Association d/b/a Confluence Health
Wenatchee, Washington, 98801
Texas Valley Clinical Research
Weslaco, Texas, 78596
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa, 50266
About this study
Official title: A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3549492 Once Daily Compared With Placebo in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with obesity or overweight. Participation in the study will last about one year.
- Conditions
- Obesity, Overweight
- Being tested
- LY3549492, Placebo
- Medical subject headings
- Obesity, Overweight
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LY3549492Drug
Administered orally
PlaceboDrug
Administered orally
| Study group | Role | What they receive |
|---|---|---|
| LY3549492 Dose 1 | Experimental | Participants will receive LY3549492 orally Receives: Drug: LY3549492 |
| LY3549492 Dose 2 | Experimental | Participants will receive LY3549492 orally Receives: Drug: LY3549492 |
| LY3549492 Dose 3 | Experimental | Participants will receive LY3549492 orally Receives: Drug: LY3549492 |
| LY3549492 Dose 4 | Experimental | Participants will receive LY3549492 orally Receives: Drug: LY3549492 |
| LY3549492 Dose 5 | Experimental | Participants will receive LY3549492 orally Receives: Drug: LY3549492 |
| Placebo | Placebo comparator | Participants will receive Placebo orally Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent Change from Baseline in Body Weight
Measured: Baseline, Week 36
Secondary outcomes (5)
Change from Baseline in Body Weight (kilograms)
Measured: Baseline, Week 36
Percentage of Participants who Achieve ≥5% Body Weight Reduction
Measured: Baseline, Week 36
Percentage of Participants who Achieve ≥10% Body Weight Reduction
Measured: Baseline, Week 36
Change from Baseline in Body Mass Index (BMI)
Measured: Baseline, Week 36
Pharmacokinetics (PK): Average Concentration of LY3549492
Measured: Week 36
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Nov 2024
- Study start13 Nov 2024
- Primary completion7 Jan 2026
- Study completion4 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ObesityStudies of the same condition, open and under way.
- More trials run by Eli Lilly and CompanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 288 participants (actual)
Sponsor and investigators
- Lead sponsor
- Eli Lilly and Company
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Study director, Eli Lilly and Company
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06683508
- Sponsor's protocol ID
- 27240
- Other IDs
- W8M-MC-GN01, W8M-MC-CWMM
- Status last verified
- May 2026
- First submitted
- 8 Nov 2024
- Last updated
- 13 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Study at a glance
From the registry record, last updated by the sponsor on 13 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY3549492 Once Daily Compared With Placebo in Adult Participants With Obesity or Overweight
- ClinicalTrials.gov ID
- NCT06683508
- Acronym / sponsor ID
- 27240
- Conditions
- Obesity, Overweight
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 288 participants (actual)
- Lead sponsor
- Eli Lilly and CompanyIndustry (pharma, biotech, devices)
- Study start
- 13 Nov 2024 (actual)
- Primary completion
- 7 Jan 2026 (actual)
- Study completion
- 4 May 2026 (actual)
- First posted
- 12 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with obesity or overweight. Participation in the study will last about one year.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| LY3549492 Dose 1 | Experimental | Drug: LY3549492Participants will receive LY3549492 orally |
| LY3549492 Dose 2 | Experimental | Drug: LY3549492Participants will receive LY3549492 orally |
| LY3549492 Dose 3 | Experimental | Drug: LY3549492Participants will receive LY3549492 orally |
| LY3549492 Dose 4 | Experimental | Drug: LY3549492Participants will receive LY3549492 orally |
| LY3549492 Dose 5 | Experimental | Drug: LY3549492Participants will receive LY3549492 orally |
| Placebo | Placebo comparator | Drug: PlaceboParticipants will receive Placebo orally |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Assigned male at birth
- Assigned female at birth, who are of non-childbearing potential
- Have a BMI of
- Have had a stable body weight for the 3 months prior to randomization (<5% body weight gain and/or loss)
Key exclusion criteria (17 listed)
- Have Type 2 Diabetes Mellitus or Type 1 Diabetes Mellitus
- Have a history of acute or chronic pancreatitis
- Have renal impairment
- Individuals who are of childbearing potential
- Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LY3549492Administered orally | Drug | LY3549492 Dose 1, LY3549492 Dose 2, LY3549492 Dose 3, LY3549492 Dose 4, LY3549492 Dose 5 |
| PlaceboAdministered orally | Drug | Placebo |
Primary outcome
Percent Change from Baseline in Body Weight
Time frame: Baseline, Week 36
5 secondary outcomes
Change from Baseline in Body Weight (kilograms)
Time frame: Baseline, Week 36
Percentage of Participants who Achieve ≥5% Body Weight Reduction
Time frame: Baseline, Week 36
Percentage of Participants who Achieve ≥10% Body Weight Reduction
Time frame: Baseline, Week 36
Change from Baseline in Body Mass Index (BMI)
Time frame: Baseline, Week 36
Pharmacokinetics (PK): Average Concentration of LY3549492
Time frame: Week 36
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 May 2026.
- A Study to Investigate Weight Management with LY3549492 Compared with Placebo in Adult Participants With Obesity or OverweightLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Related trials for Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) study director
Eli Lilly and Company
49 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing LY3549492 in people with Obesity and Overweight, run by Eli Lilly and Company at 49 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 49 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent Change from Baseline in Body Weight (time frame: Baseline, Week 36). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2026.